Goldman Sachs Group Inc Concert Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 May 14, 2024	BUY	$4.34 - $5.84 $822,651 - $1.11 Million	189,551 Added 56.74%	523,630 $3.06 Million
Q4 2022 Feb 13, 2023	BUY	$4.34 - $5.84 $822,651 - $1.11 Million	189,551 Added 56.74%	523,630 $3.06 Million
Q3 2022 May 14, 2024	BUY	$4.27 - $7.2 $625,943 - $1.06 Million	146,591 Added 78.19%	334,079 $2.24 Million
Q3 2022 Nov 10, 2022	BUY	$4.27 - $7.2 $625,943 - $1.06 Million	146,591 Added 78.19%	334,079 $0
Q2 2022 May 14, 2024	BUY	$2.8 - $6.36 $524,966 - $1.19 Million	187,488 New	187,488 $789,000
Q2 2022 Aug 15, 2022	BUY	$2.8 - $6.36 $524,966 - $1.19 Million	187,488 New	187,488 $789,000
Q4 2021 Feb 14, 2022	SELL	$2.69 - $4.22 $42,429 - $66,562	-15,773 Closed	0 $0
Q3 2021 Nov 10, 2021	BUY	$3.17 - $4.15 $50,000 - $65,457	15,773 New	15,773 $52,000

Ticker CNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,934,600
Description
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.